#Chronic Idiopathic Constipation Treatment Market research

[soumyafwr]

https://biiut.com/read-blog/56294_global-chronic-idiopathic-constipation-treatment-market-size-overview-key-player.html

Chronic Idiopathic Constipation Treatment Market 

[jesse-pinkman123]

Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis-2027

Peptide-Based Gastrointestinal Disorders Therapeutics Market Regional Analysis

North America Peptide-Based Gastrointestinal Disorders Therapeutics Market is expected to exhibit good growth over the forecast period, owing to presence of major players and adoption of strategies such as mergers and collaborations by them for novel peptide-based therapeutics. For instance, in February 2018, Cipher Pharmaceuticals Inc. acquired exclusive Canadian rights of the U.S. Food and Drug Administration approved drug Trulance (plecanatide) from Synergy Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will develop, market, distribute, and sell Trulance (plecanatide) in the Canadian Market.

Asia Pacific peptide-based gastrointestinal disorders therapeutics market is expected to exhibit significant growth over the forecast period, owing to increasing investments made by players in the region to receive approval of novel peptide-based therapeutics. For instance, in 2014, Ironwood Pharmaceuticals, Inc. received US$ 15 million from Astellas Pharma Inc., a Japan-based pharmaceutical company, for initiating Phase III clinical trial of Linzess (linaclotide) in Japan, and receive its approval from Japanese Ministry of Health, Labor, and Welfare in 2016. Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. were under strategic partnership since 2009 for developing and commercializing linaclotide in Japan.

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptide-based gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of various GIT disorders such as short bowel syndrome, chronic constipation, and irritable bowel syndrome. In the recent past, some peptide-based therapeutics such as Trulance, Linaclotide, and Teduglutide received approval for the treatment of GIT disorders.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2028

Trulance is a guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic constipation in adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of guanylate cyclase C receptors in the intestine. It is a minimally absorbed agonist of guanylate cyclase C receptors in the intestine and is used for the treatment of chronic constipation and irritable bowel syndrome. Teduglutide is a new recombinant analogue for glucagon-like peptide (GLP) -2, a natural occurring peptide, which is secreted primarily by the lower gastrointestinal tract.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics

Frequent approval and launch of novel peptide-based gastrointestinal disorders therapeutics in key regions is expected to drive the global peptide-based gastrointestinal disorders therapeutics market growth over the forecast period.

For instance, in 2017, Synergy Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

In 2012, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food and Drug Administration approval for its drug called Linzess (linaclotide). Linzess (linaclotide) is a guanylate cyclase-C agonist used for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/peptide-based-gastrointestinal-disorders-therapeutics-market-2028

In 2016, Ironwood Pharmaceuticals, Inc.’s partner, Astellas Pharma Inc., received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for Linzess (linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan.

In 2012, NPS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its drug Gattex (Teduglutide (rDNA origin)). Gattex 0.05 mg/kg/d injection is a new, recombinant analog of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal lining. It is indicated for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Sucg frequent approval is expected to cather peptide-based gastrointestinal disorders therapeutics market growth in near future.

Furthermore, increasing prevalence of gastrointestinal disorders is expected to rise the demand for peptide-based drugs, which will in turn drive the global peptide-based gastrointestinal disorders therapeutics market growth. For instance, according to the data published by the International Foundation for Functional Gastrointestinal Disorder in 2016, irritable bowel syndrome (IBS) is the most common functional gastrointestinal (GI) disorder and globally, around 10-15% of the population suffers from IBS.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Key Players

Key players operating in the global peptide-based gastrointestinal disorders therapeutics market include Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Astellas Pharma Inc., Allergan plc., and Cipher Pharmaceuticals Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2028

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

[wiseguyreportresearch]

Global Opioid-Induced Constipation Treatment MarketAnalysis, Historic Data and Forecast 2020

Opioid-Induced Constipation Treatment Market Reports

Global Opioid-Induced Constipation Treatment Market are the drugs used for its pain relieving properties in non-cancer and chronic pain. The adverse effects associated with the opioids are decreasing gastrointestinal tract’s motility, making patient’s strain, and making of solid discharges. Furthermore, long-term use of opioids cause harm to the sensory system, limits the release of endogenous opioids such as endorphins. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The symptoms associated with the opioid-induced constipation are included dry and hard tools, leathery feeling, painful defecation, bulged abdomen, and loss of appetite.

ALSO READ : https://icrowdnewswire.com/2021/01/06/opioid-induced-constipation-treatment-industry-treatment-outlook-analysis-research-review-to-2023/

The opioid-induced constipation treatment market growing at a significant CAGR due to rise in the aging population using opioid analgesics for chronic pains. Increase in the illicit use of medications, prolonged usage of opioids in the treatment of pain, an increase in the prevalence of cancer is anticipated to boost the global opioid-induced constipation treatment market. Furthermore, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the opioid-induced constipation treatment market over the forecast period. However, lack of awareness regarding opioid-induced constipation in patients, the absence of treatment innovations, a high cost of newer pharmaceuticals, adverse effects, including nausea, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the opioid-induced constipation treatment market.

ALSO READ : http://www.marketwatch.com/story/specialty-insurance-market-key-players-industry-size-trend-share-and-global-growth-opportunities-forecast-to-2026-2021-01-29

The opioid-induced constipation treatment market is segmented on the basis of drug type, formulation type, route of administration, and distribution channel

Based on drug type, opioid-induced constipation treatment market has been segmented into the following

Peripherally restricted μ-opioid receptor antagonists

Non-selective opioid antagonists

μ -opioid receptor antagonists

Locally acting chloride channel activators

Based on formulation type, opioid-induced constipation treatment market has been segmented into the following

Solids

Semi-solids

Liquids

Based on route of administration, opioid-induced constipation treatment market has been segmented into the following

Oral

Parenteral (Subcutaneous Injection)

Based on distribution channel, opioid-induced constipation treatment market has been segmented into the following

Drugstore

Retail pharmacies

Hospital pharmacies

ALSO READ :http://www.marketwatch.com/story/car-rental-market-2021-industry-size-share-price-trend-and-forecast-to-2026-2021-01-27

The Global Opioid-Induced Constipation Treatment Market is in the growing stage, several players are actively engaged in the development of the opioid-induced constipation treatment market products. Major acquisitions and collaborations among companies to commercialize opioid-induced constipation treatment market products to drive the market growth. For instance, in March 2015, the co-commercialization agreement for Movenpick signed by AstraZeneca and Daiichi Sankyo, and in October 2014, the entry of Takeda and Sucampo into a global licensing, development, and commercialization agreement for Amitiza are expected to boost the global opioid-induced constipation treatment market. Launching of new products, approval of new drugs from various regulatory bodies, and pipeline products under clinical trials are the key factors fuelling the growth of the opioid-induced constipation treatment market. For instance, Linaclotide was approved by the FDA in August 2012 and by the European Medicines Agency for the treatment in adults with constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Geographically, Global Opioid-Induced Constipation Treatment Market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in the opioid-induced constipation treatment market followed by Europe and Asia-Pacific. North America holds the largest share due to expanding the base of opioid-induced constipation patients, According to the American Society of Interventional Pain Physician, in 2013, the U.S. alone was responsible for nearly 80% of the global consumption of opioids. Europe accounts for the significant share in the opioid-induced constipation treatment market owing to increased demand for opioid analgesics in various European countries such as UK, France, Spain, Germany etc. However, growing elderly population in India and China, and rise in healthcare spending are creating the huge growth opportunity for the players in Asia-Pacific region. Apart from that, Latin America and the Middle East are the potential areas for the growth of opioid-induced constipation treatment market because of the increase in opioid-induced constipation sufferers.

ALSO READ : http://www.marketwatch.com/story/global-hydropower-generation-market-industry-analysis-size-share-growth-trends-and-forecast-2021-2027-2021-01-23

Some of the players in the opioid-induced constipation treatment market are GlaxoSmithKline plc (U.K.), AstraZeneca U.K), Pfizer Inc. (U.S.), SLA Pharma AG (U.K.), AIKO Biotechnology, Inc. (U.S.), Cubist Pharmaceuticals (Merck & Co.) (U.S.), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Bayer AG (Germany), Valeant Pharmaceuticals International Inc. (Canada), Abbott Laboratories (U.S.), Purdue Pharma LP (U.S.) Shionogi Inc. (U.S.) and Cosmo Pharmaceuticals N.V. (Ireland) to name a few.

In March 2017, FDA approved Symphonic (Naldemedine) for the treatment of Opioid-Induced Constipation, which was manufactured by Purdue Pharma LP and Shionogi

In March 2016, AstraZeneca announced that it has entered into an agreement with ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig (Naloxegol) in the European Union (EU)

Report Outline:

The report provides granular level information about the market size, regional market share, and forecast from 2017-2023

The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup’s details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

ALSO READ : http://www.marketwatch.com/story/global-female-skincare-market-projection-by-latest-technology-opportunity-application-growth-services-project-revenue-analysis-report-forecast-to-2026-2021-01-19

[dbmronkar]

Global ELISA Tests Market is Rising Market to Rapidly Growing $2529.27 million by 2026 with Top Key Players Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific,  ALPCO, Bio-Rad Laboratories, bioMérieux, Merck KGaA,  BioLegend, LOEWE Biochemica, Creative Diagnostics., Arigo biolaboratories Corp.

Analysis of Global ELISA Tests Market report:

Global ELISA tests market is expected to rise from to an estimated value of USD 2529.97 million by 2026 registering a substantial CAGR in the forecast period of 2019-2026. This rise in the market can be attributed to rising prevalence of cancer, rising ageing population and technological advancements.

Definition:

ELISA Tests (Enzyme Linked Immunosrbent Assay) is a test that identifies detects and measures antibodies, proteins, peptides, hormones in the biological samples. It serves as a diagnostic tool detecting whether sample has antibodies that are related to a particular infectious condition. ELISA is a biochemical reaction in which antigen is adsorbed on a solid surface. ELISA test is used extensively in the diagnosis of HIV, varicella-zoster virus, which causes chickenpox and shingles, rotavirus, Zika virus, syphilis, pregnancy tests, in the measurement of cytokine, soluble proteins etc. ELISA is mostly used as screening device prior to in-depth tests.

Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-elisa-tests-market

Leading Key players profiled in this report are:

Few of the major market competitors currently working in the ELISA tests market are Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific, Inc., ALPCO, BD, Bio-Rad Laboratories, Inc., bioMérieux SA, Enzo Life Sciences, Inc., Merck KGaA,  BioLegend, Inc., LOEWE Biochemica GmbH, Creative Diagnostics., Arigo biolaboratories Corp., ELISA Technologies, Inc., RayBiotech, Inc., R&D Systems, Inc., AESKU.GROUP GmbH & Co. KG, Cell Technology., Arbor Assays, Eurofins Scientific and Biogenuix amongst others.

Market Drivers

·        The rising prevalence of cancer due to unhealthy lifestyle, lack of exercise and increased consumption of drugs and alcohol, would foster the growth of enzyme-linked immunosorbent assay (ELISA) testing market

·        Rising expenditure in R&D activities in the drug discovery market would boost the growth of this market

·        Rising ageing population enhances the growth of this market as they are more prone to communicable and non-communicable diseases such as cardiovascular disease, lung disease, and cancer, which drives the demand for the prevention, diagnosis, and treatment of such diseases

·       Advancements in technology and automations in the healthcare industry would drive the growth of this market

Market Restraints

·        Lack of availability and cost-effective diagnostic tests hinders the growth of this market.

·        Substitution by new technologically advanced techniques including multiplex proteomic array platforms would restrain its growth

Global ELISA Tests Market Segmentation:

By Test Type

·        Direct ELISA

·        Sandwich ELISA

·        Indirect ELISA

·        Multiple & Portable ELISA

·        Competitive ELISA

By Application

·        Immunology

·        Inflammation

·        Diagnostics

·        Vaccine Development

·        Toxicology

·        Drug Monitoring & Pharmaceutical Industry

·        Transplantation

·        Infectious Diseases

·        Cancer

·        Protein Quantitation

·        Other

By Technology

·        Chemiluminescent

·        Colorimetric

·        Fluorescent

By End-User

·        Hospitals & Diagnostic Centers

·        Research Laboratories

By Geography

·        North America

·        South America

·        Europe

·        Asia-Pacific

Company Share Analysis:

Global ELISA tests market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ELISA tests market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-elisa-tests-market

The Global ELISA Tests Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global ELISA Tests Market. The industry changing factors for the market segments are explored in this report.  This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.

Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Access Full Report :- https://www.databridgemarketresearch.com/reports/global-elisa-tests-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.

Contact:

Data Bridge Market Research

+1-888-387-2818

Find More Reports Related To This Category

Global Nanomedicine Market

Global Chronic Idiopathic Constipation Treatment Market

[dbmronkar08]

Global ELISA Tests Market is Booming Market to Rapidly Growing $2529.27 million by 2026 with Top Key Players Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific,  ALPCO, Bio-Rad Laboratories, bioMérieux, Merck KGaA,  BioLegend, LOEWE Biochemica, Creative Diagnostics., Arigo biolaboratories Corp.

Analysis of Global ELISA Tests Market report:

Global ELISA tests market is expected to rise from to an estimated value of USD 2529.97 million by 2026 registering a substantial CAGR in the forecast period of 2019-2026. This rise in the market can be attributed to rising prevalence of cancer, rising ageing population and technological advancements.

Definition:

ELISA Tests (Enzyme Linked Immunosrbent Assay) is a test that identifies detects and measures antibodies, proteins, peptides, hormones in the biological samples. It serves as a diagnostic tool detecting whether sample has antibodies that are related to a particular infectious condition. ELISA is a biochemical reaction in which antigen is adsorbed on a solid surface. ELISA test is used extensively in the diagnosis of HIV, varicella-zoster virus, which causes chickenpox and shingles, rotavirus, Zika virus, syphilis, pregnancy tests, in the measurement of cytokine, soluble proteins etc. ELISA is mostly used as screening device prior to in-depth tests.

Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-elisa-tests-market

Market Drivers

·        The rising prevalence of cancer due to unhealthy lifestyle, lack of exercise and increased consumption of drugs and alcohol, would foster the growth of enzyme-linked immunosorbent assay (ELISA) testing market

·        Rising expenditure in R&D activities in the drug discovery market would boost the growth of this market

·        Rising ageing population enhances the growth of this market as they are more prone to communicable and non-communicable diseases such as cardiovascular disease, lung disease, and cancer, which drives the demand for the prevention, diagnosis, and treatment of such diseases

·       Advancements in technology and automations in the healthcare industry would drive the growth of this market

Market Restraints

·        Lack of availability and cost-effective diagnostic tests hinders the growth of this market.

·        Substitution by new technologically advanced techniques including multiplex proteomic array platforms would restrain its growth

Leading Key players profiled in this report are:

Few of the major market competitors currently working in the ELISA tests market are Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific, Inc., ALPCO, BD, Bio-Rad Laboratories, Inc., bioMérieux SA, Enzo Life Sciences, Inc., Merck KGaA,  BioLegend, Inc., LOEWE Biochemica GmbH, Creative Diagnostics., Arigo biolaboratories Corp., ELISA Technologies, Inc., RayBiotech, Inc., R&D Systems, Inc., AESKU.GROUP GmbH & Co. KG, Cell Technology., Arbor Assays, Eurofins Scientific and Biogenuix amongst others.

Global ELISA Tests Market Segmentation:

By Test Type

·        Direct ELISA

·        Sandwich ELISA

·        Indirect ELISA

·        Multiple & Portable ELISA

·        Competitive ELISA

By Application

·        Immunology

·        Inflammation

·        Diagnostics

·        Vaccine Development

·        Toxicology

·        Drug Monitoring & Pharmaceutical Industry

·        Transplantation

·        Infectious Diseases

·        Cancer

·        Protein Quantitation

·        Other

By Technology

·        Chemiluminescent

·        Colorimetric

·        Fluorescent

By End-User

·        Hospitals & Diagnostic Centers

·        Research Laboratories

By Geography

·        North America

·        South America

·        Europe

·        Asia-Pacific

Company Share Analysis:

Global ELISA tests market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ELISA tests market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-elisa-tests-market

The Global ELISA Tests Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global ELISA Tests Market. The industry changing factors for the market segments are explored in this report.  This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.

Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Access Full Report :- https://www.databridgemarketresearch.com/reports/global-elisa-tests-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.

Contact:

Data Bridge Market Research

+1-888-387-2818

Find More Reports Related To This Category

Global Nanomedicine Market

Global Chronic Idiopathic Constipation Treatment Market

[researchindustry]

Global Induced Pluripotent Market Growth, Trends and Absolute Opportunity up to 2026

Global induced pluripotent market is expected to rise to an estimated value of USD 2.33 billion by 2026, registering a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing prevalence of chronic diseases and ailments requiring the development of modern technologically advanced therapeutic options.

Key Market Competitors: Global Induced Pluripotent Market

Few of the major competitors currently working in the induced pluripotent market are Bristol-Myers Squibb Company; CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.; Organogenesis Holdings; Merck KGaA; FUJIFILM Holdings Corporation; Fate Therapeutics; KCI Licensing, Inc.; Japan Tissue Engineering Co., Ltd.; Vericel; ViaCyte, Inc.; STEMCELL Technologies Inc.; Horizon Discovery Group plc; Lonza; Takara Bio Inc.; Promega Corporation and QIAGEN.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-induced-pluripotent-market

Induced pluripotent are a specialized form of stem cells that are extracted from either skin or blood cells, and are then modified into the pluripotent form which gives them the capability of being used for the treatment where any different kind of human cells are required. In the pluripotent form, they can be modified to any kind of cell form that is utilized for the treatment of different diseases/disorders.

Competitive Analysis: Global Induced Pluripotent Market

Global induced pluripotent market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of induced pluripotent market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation: Global Induced Pluripotent Market

·         By Product Category (Cell Culture, Differentiation, Reprogramming, Engineering, Cell Analysis, Others)

·         By Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Neurons, Others)

·         By Application (Drug Development, Regenerative Medicine, Toxicity Testing, Academic Research, Stem Cell Bio-Banking)

·         By End-User (Academic & Research Institutes, Biotechnology Companies, Hospitals)

·         By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Speak to Analyst @ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-induced-pluripotent-market

Market Drivers

·         Rise in the expenditure incurred by various private and government sources on R&D is expected to drive the growth of the market

·         High levels of understanding and awareness regarding the composition of the iPSC (Induced Pluripotent Stem Cell) has resulted in a rise of demand of the product from various end-users; this factor is expected to drive the growth of the market

·         Utilization of these cells for the creation of customized tissues and helping in understanding of human development; this factor is expected to drive the growth of the market

Market Restraints

·         Complications and large costs associated with the development and manufacturing of these products are expected to restrain the growth of the market

·         Chances of health risks due to the acceptance of these products in the recipient’s body along with lack of efficiency in the process are factors restraining the growth of the market

Reasons to Purchase this Report

·         Current and future of global induced pluripotent market outlook in the developed and emerging markets

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period

·         The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

·         All segmentation provided above in this report is represented at country level

·         All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Browse full report @ https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

 Related Reports:

 Global Chronic Idiopathic Constipation Treatment Market

 Global Diabetic Gastroparesis Treatment Market

[martynnx-blog]

Chronic Idiopathic Constipation (CIC) Treatment Market Till, 2018-2026 - New Study By Coherent Market Insights

Constipation is condition wherein the stool frequency reduces up to three times per week with difficulty in stool passing. Chronic constipation is a highly common functional gastrointestinal disorder that adversely affects patient’s life. Chronic idiopathic constipation is defined as the presence of chronic symptoms of constipation with no well-defined underlying cause. The symptoms of chronic idiopathic constipation includes infrequent bowel movements, hard stools, straining during defecation, feeling of incomplete evacuation, abdominal discomfort, and bloating sensation. Chronic idiopathic constipation is diagnosed by laboratory tests, endoscopy, radiological tests, magnetic resonance imaging, and physiological testing. Currently, very few approved treatment options are available for chronic idiopathic constipation, which is expected to be a major factor restrain growth of the chronic idiopathic constipation treatment market. However, this gives opportunity for the market player to come up with the novel treatment to grab the foothold in growing chronic idiopathic constipation treatment market.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1791

Chronic Idiopathic Constipation (CIC) Treatment Market Dynamics

Increasing clinical trials and approval of drug candidates by pharmaceutical companies to fulfil unmet medical needs of the chronic idiopathic constipation treatment is a key factor driving the market growth over the forecast period. For instance, March 2018, Shire plc received new drug application from U.S. FDA for its drug candidate, SHP555 (prucalopride) for the indication of chronic idiopathic constipation in adults. Moreover, in 2015, SHP555 (prucalopride)received approval from European Commission for the symptomatic treatment of chronic constipation in adults with failure of laxative treatment. Furthermore, Renexxion is conducting phase 2 clinical trial for Naronapride (ATI-7505) for the treatment of multiple gastrointestinal disorders, which includes chronic idiopathic constipation. In 2017, FDA approved Ironwood and Allergan’s Linzess (linaclotide) for the treatment of chronic idiopathic constipation. However, 50% of patients with chronic constipation dissatisfied with their current treatment, mainly because of the lack of efficacy, which highlights a continued medical need for more effective and safer therapeutic agents.

However, the use of alternate therapy such as home-based remedies and herbal medication such as herbal laxative, probiotic foods etc. are expected to be major factors hindering the chronic idiopathic constipation treatment market growth.

Chronic Idiopathic Constipation (CIC) Treatment Market – Regional Analysis

Regional segmentation of chronic idiopathic constipation treatment market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America chronic idiopathic constipation treatment market holds dominant position owing to high percentage of population suffering from chronic constipation. For instance, according to European Journal of Pharmacology, 2017, in the U.S. 12%–19% of population suffers from chronic constipation. This is expected to aid in growth of the market in the region over the forecast period. However, Asia Pacific is expected to witness the fastest growth, owing to increasing prevalence of constipation in the Asian countries. According to Journal of Neurogastroenterology and Motility article 2016, in Asian countries such as China, Korea, Hong Kong, and India, the prevalence of constipation reportedly ranges from 8.2% to 16.8%. This is expected to support growth of the chronic idiopathic constipation treatment market size over the forecast period.

Chronic Idiopathic Constipation (CIC) Treatment Market – Competitive Analysis

Key players in chronic idiopathic constipation treatment market are Ironwood Pharmaceuticals, Allergan, Synergy Pharmaceuticals, Inc., Shire plc, and Mallinckrodt plc. The presence of very few market player provides wide opportunity for new entrant in chronic idiopathic constipation market. Moreover, in February 2018, Mallinckrodt plc, global specialty pharmaceutical company, announced acquisition of Sucampo Pharmaceuticals, Inc., a biopharmaceutical company. The acquisition assets includes its FDA approved blockbuster drug Amitiza (lubiprostone) for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C). The Sucampo Pharmaceuticals, Inc. also partnered with Par Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories Ltd. As a part of the agreement both the partners were granted a non-exclusive license to market Par’s generic version of lubiprostone in the U.S. from January, 2021. Such inorganic strategies of market players are expected to boost growth of the market significantly over the forecast period. In 2012, Ferring Pharmaceuticals acquired the rights for development and commercialization of Elobixibat, first-in-class compound for chronic idiopathic constipation from Albireo AB, a Swedish biotechnology company. Further, in 2013, Ferring Pharmaceuticals, initiated phase III clinical trials of Elobixibat.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1791

[soumyafwr]

Chronic Idiopathic Constipation Treatment Market 

[gopriyu-blog]

Global Opioid Induced Constipation Drug Market

Global Opioid Induced Constipation Drug Market was valued at US$ 2.1Bn in 2017 and is expected to reach US$ 3.2Bn by 2026 at a CAGR of 5.4%.

 The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global opioid induced constipation drug market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global opioid induced constipation drug market.

 Global Opioid Induced Constipation Drug Market

 The number of patients suffering from opioid induced constipation is growing across the globe. Close to 100 mn U.S. patients in 2013 were suffering from opioid induced constipation, according to the American Academy of Pain Medicine. They added that this number is anticipated to increase as the number of people consuming opioid drugs increases. With an increasing awareness of the commercial availability of a large type of opioid drugs, people have resorted to using them for longer terms to treat chronic pains.

 Increasing incidences of diseases associated with old age, impaired body functions, and rise in the use of medicines such as antidepressants and anticholinergic have collectively led to a high prevalence of constipation among the elderly population. This drives growth in the opioid induced constipation market globally. The use of laxatives for opioid induced constipation is a major challenge that is reducing sales of approved drugs meant for the treatment of opioid induced constipation.

 Lubiprostone segment is leading the global opioid induced constipation drug market. Lubiprostone under the brand name Amitiza is indicated for treating opioid induced constipation drug, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is projected that the segment will take over the market share of methylnaltrexone bromide. Moreover, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for many patient types such as pregnant women and patients less than 17 years of age. So, future approvals are expected to lead the market.

 Region-wise, North America is the dominant regional opioid induced constipation drugs market through the forecast period. Early bird approval of opioid induced constipation drugs by the USFDA and high consumption of opioids in the US is the prime growth factors for the opioid induced constipation drugs market in North America. Besides, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of opioid induced constipation drugs.

Scope of Global Opioid Induced Constipation Drug Market

 Global Opioid Induced Constipation Drug Market, by Drug type

 • Methylnaltrexone Bromide

• Lubiprostone

• Naloxegol

• Naldemedine

• Docusate Sodium

• Others

Global Opioid Induced Constipation Drug Market, by Prescription type

 • Prescribed

• Over The Counter

Global Opioid Induced Constipation Drug Market, by Region

 • North America

• Europe

• Asia Pacific

• Middle East and Africa

• South America

Key players operating in Global Opioid Induced Constipation Drug Market

 • GlaxoSmithKline, Inc.

• AstraZeneca plc, Inc.

• Pfizer, Inc.

• S.L.A. Pharma AG

• AIKO Biotechnology

• Cubist Pharmaceuticals

• Salix Pharmaceuticals, Inc.

• Takeda Pharmaceutical Company Limited

   This Report Is Submitted By Maximize Market Research

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Maharashtra 411051, India.

[coolluminaryland-blog1]

Constipation Treatment Market: Industry Players Introduce Key Business Strategies to Advertise their Products

Global Constipation Treatment Market: Snapshot

The demand in the global market for constipation treatment is projected to increment at a healthy CAGR of 7.1% during the forecast period of 2017 to 2025. This prosperity of the constipation treatment market is primarily a reflection of escalating geriatric population across the globe, as people aged over 50 years are highly prone to irregular bowel movement. Consistent research and development to develop novel drugs that are more efficient, improving healthcare infrastructure in various emerging economies, and growing awareness among the end-users are some of the other factors favoring the global constipation treatment market. On the other hand, continued reliance of the patients on over-the-counter drugs and vast unmet demands in rural areas of developing countries is hindering the proper prosperity of the global constipation treatment market. Evaluated to have a worth of US$12.58 bn in 2016, the global constipation treatment market is estimated to reach a valuation of US$22.93 bn by the end of the forecast period, which is 2025.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16442

Laxatives Remain Highly Profitable Therapeutic Segment

On the basis of therapeutic option, the global market for constipation treatment is segmented into laxatives, peripherally acting mu opioid receptor antagonists, chloride channel activators, GC-C agonists, and 5-HT4 receptor agonists. In 2016, the laxatives segment, which is further categorized into bulk forming agents, stimulant laxatives, and osmotic laxatives, accounted for the maximum demand-share. Over the course of the forecast period, the laxatives segment is anticipated to be most promising and dominate the market share. Affordability for the masses owing to low cost and wide availability are two key factors leading to the prosperity of this laxatives segment. That being said, GC-C agonists segment is projected for the best CAGR of 8.7% from 2017 to 2025.

Based on the type of disease, the global constipation treatment market is bifurcated into irritable bowel syndrome with constipation, chronic idiopathic constipation, and opioid induced constipation. The opioid induced constipation segment is projected to expand at CAGR of 7.5% during the forecast period from 2017 to 2025. Based on distribution channel, global market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies segment is projected to hold major share of global constipation treatment market in the near future.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16442

Asia Pacific Projected for Most Impressive Growth Rate

Geographically, the global constipation treatment market has been classified into six major regions, viz. North America, Asia Pacific, Europe, Latin America, The Middle East & Africa, and Commonwealth of Independent States. In 2017, North America served the maximum demand in the constipation treatment market, owing to high prevalence of chronic constipation, high per capita healthcare expenditure, and availability of specialty constipation medicines. The North America constipation market is estimated to be worth US$9.98 bn by the end of 2025. Europe currently is second most lucrative region for the vendors operating in this market, however, Asia Pacific is anticipated to turn into a region-of-focus, with its considerably established market in emerging economies. Japan, India, and China are identified as three emerging country-wide markets for constipation treatment.

Some of the key players currently holding a position of strength in the global constipation market are: Bayer AG, Ironwood Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Limited, Sanofi, AstraZeneca, Abbott Laboratories, Sucampo Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, Inc., Janssen Pharmaceutical Company, Daewoong Pharmaceuticals Co. Ltd., Prestige Brands Holdings, Inc., Shionogi & Co., Ltd., Renexxion, LLC., Albireo Pharma, Inc., and Cosmo Pharmaceuticals NV.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 USA – Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/

[pragya1-blog]

Constipation Treatment Market Opportunity will Rise to  US$22.93 bn by 2025

Global Constipation Treatment Market: Snapshot

The demand in the global market for constipation treatment is projected to increment at a healthy CAGR of 7.1% during the forecast period of 2017 to 2025. This prosperity of the constipation treatment market is primarily a reflection of escalating geriatric population across the globe, as people aged over 50 years are highly prone to irregular bowel movement. Consistent research and development to develop novel drugs that are more efficient, improving healthcare infrastructure in various emerging economies, and growing awareness among the end-users are some of the other factors favoring the global constipation treatment market. On the other hand, continued reliance of the patients on over-the-counter drugs and vast unmet demands in rural areas of developing countries is hindering the proper prosperity of the global constipation treatment market. Evaluated to have a worth of US$12.58 bn in 2016, the global constipation treatment market is estimated to reach a valuation of US$22.93 bn by the end of the forecast period, which is 2025.

Browse Press Release @

https://www.transparencymarketresearch.com/pressrelease/constipation-treatment-market.htm

Laxatives Remain Highly Profitable Therapeutic Segment

On the basis of therapeutic option, the global market for constipation treatment is segmented into laxatives, peripherally acting mu opioid receptor antagonists, chloride channel activators, GC-C agonists, and 5-HT4 receptor agonists. In 2016, the laxatives segment, which is further categorized into bulk forming agents, stimulant laxatives, and osmotic laxatives, accounted for the maximum demand-share. Over the course of the forecast period, the laxatives segment is anticipated to be most promising and dominate the market share. Affordability for the masses owing to low cost and wide availability are two key factors leading to the prosperity of this laxatives segment. That being said, GC-C agonists segment is projected for the best CAGR of 8.7% from 2017 to 2025.

Request for Sample Copy of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16442

Based on the type of disease, the global constipation treatment market is bifurcated into irritable bowel syndrome with constipation, chronic idiopathic constipation, and opioid induced constipation. The opioid induced constipation segment is projected to expand at CAGR of 7.5% during the forecast period from 2017 to 2025. Based on distribution channel, global market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies segment is projected to hold major share of global constipation treatment market in the near future.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16442

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research State Tower, 90 State Street, Suite 700 Albany, NY 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: www.transparencymarketresearch.com

[dbmronkar]

Global ELISA Tests Market is Booming Market to Rapidly Growing $2529.27 million by 2026 with Top Key Players Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific,  ALPCO, Bio-Rad Laboratories, bioMérieux, Merck KGaA,  BioLegend, LOEWE Biochemica, Creative Diagnostics., Arigo biolaboratories Corp.

Definition:

ELISA Tests (Enzyme Linked Immunosrbent Assay) is a test that identifies detects and measures antibodies, proteins, peptides, hormones in the biological samples. It serves as a diagnostic tool detecting whether sample has antibodies that are related to a particular infectious condition. ELISA is a biochemical reaction in which antigen is adsorbed on a solid surface. ELISA test is used extensively in the diagnosis of HIV, varicella-zoster virus, which causes chickenpox and shingles, rotavirus, Zika virus, syphilis, pregnancy tests, in the measurement of cytokine, soluble proteins etc. ELISA is mostly used as screening device prior to in-depth tests.

Analysis of Global ELISA Tests Market report:

Global ELISA tests market is expected to rise from to an estimated value of USD 2529.97 million by 2026 registering a substantial CAGR in the forecast period of 2019-2026. This rise in the market can be attributed to rising prevalence of cancer, rising ageing population and technological advancements.

Get Sample Copy of Report Here: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-elisa-tests-market

Market Drivers

·        The rising prevalence of cancer due to unhealthy lifestyle, lack of exercise and increased consumption of drugs and alcohol, would foster the growth of enzyme-linked immunosorbent assay (ELISA) testing market

·        Rising expenditure in R&D activities in the drug discovery market would boost the growth of this market

·        Rising ageing population enhances the growth of this market as they are more prone to communicable and non-communicable diseases such as cardiovascular disease, lung disease, and cancer, which drives the demand for the prevention, diagnosis, and treatment of such diseases

·       Advancements in technology and automations in the healthcare industry would drive the growth of this market

Market Restraints

·        Lack of availability and cost-effective diagnostic tests hinders the growth of this market.

·        Substitution by new technologically advanced techniques including multiplex proteomic array platforms would restrain its growth

Leading Key players profiled in this report are:

Few of the major market competitors currently working in the ELISA tests market are Ortho Clinical Diagnostics, Thermo Fisher Scientific, ZEUS Scientific, Inc., ALPCO, BD, Bio-Rad Laboratories, Inc., bioMérieux SA, Enzo Life Sciences, Inc., Merck KGaA,  BioLegend, Inc., LOEWE Biochemica GmbH, Creative Diagnostics., Arigo biolaboratories Corp., ELISA Technologies, Inc., RayBiotech, Inc., R&D Systems, Inc., AESKU.GROUP GmbH & Co. KG, Cell Technology., Arbor Assays, Eurofins Scientific and Biogenuix amongst others.

Global ELISA Tests Market Segmentation:

By Test Type

·        Direct ELISA

·        Sandwich ELISA

·        Indirect ELISA

·        Multiple & Portable ELISA

·        Competitive ELISA

By Application

·        Immunology

·        Inflammation

·        Diagnostics

·        Vaccine Development

·        Toxicology

·        Drug Monitoring & Pharmaceutical Industry

·        Transplantation

·        Infectious Diseases

·        Cancer

·        Protein Quantitation

·        Other

By Technology

·        Chemiluminescent

·        Colorimetric

·        Fluorescent

By End-User

·        Hospitals & Diagnostic Centers

·        Research Laboratories

By Geography

·        North America

·        South America

·        Europe

·        Asia-Pacific

Company Share Analysis:

Global ELISA tests market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ELISA tests market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Get 20% Extra Discount for Early Buyer, Know More @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-elisa-tests-market

The Global ELISA Tests Market report provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading markets players within the Global ELISA Tests Market. The industry changing factors for the market segments are explored in this report.  This analysis report covers the growth factors of the worldwide market based on end-users. Market opportunities and recommendations for new investments are also encompassed in this report.

Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Access Full Report :- https://www.databridgemarketresearch.com/reports/global-elisa-tests-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.

Contact:

Data Bridge Market Research

+1-888-387-2818

Find More Reports Related To This Category

Global Nanomedicine Market

Global Chronic Idiopathic Constipation Treatment Market

[healthcaretrends-blog]

Chronic Idiopathic Constipation (CIC) Treatment Market, By Drug Type Linaclotide, Plecanatide

Constipation is condition wherein the stool frequency reduces up to three times per week with difficulty in stool passing. Chronic constipation is a highly common functional gastrointestinal disorder that adversely affects patient’s life. Chronic idiopathic constipation is defined as the presence of chronic symptoms of constipation with no well-defined underlying cause. The symptoms of chronic idiopathic constipation includes infrequent bowel movements, hard stools, straining during defecation, feeling of incomplete evacuation, abdominal discomfort, and bloating sensation. Chronic idiopathic constipation is diagnosed by laboratory tests, endoscopy, radiological tests, magnetic resonance imaging, and physiological testing. Currently, very few approved treatment options are available for chronic idiopathic constipation, which is expected to be a major factor restrain growth of the chronic idiopathic constipation treatment market. However, this gives opportunity for the market player to come up with the novel treatment to grab the foothold in growing chronic idiopathic constipation treatment market.

Click To Continue Reading :

https://www.coherentmarketinsights.com/ongoing-insight/chronic-idiopathic-constipation-cic-treatment-market-1791

Chronic Idiopathic Constipation (CIC) Treatment Market Dynamics

Increasing clinical trials and approval of drug candidates by pharmaceutical companies to fulfil unmet medical needs of the chronic idiopathic constipation treatment is a key factor driving the market growth over the forecast period. For instance, March 2018, Shire plc received new drug application from U.S. FDA for its drug candidate, SHP555 (prucalopride) for the indication of chronic idiopathic constipation in adults. Moreover, in 2015, SHP555 (prucalopride)received approval from European Commission for the symptomatic treatment of chronic constipation in adults with failure of laxative treatment. Furthermore, Renexxion is conducting phase 2 clinical trial for Naronapride (ATI-7505) for the treatment of multiple gastrointestinal disorders, which includes chronic idiopathic constipation. In 2017, FDA approved Ironwood and Allergan’s Linzess (linaclotide) for the treatment of chronic idiopathic constipation. However, 50% of patients with chronic constipation dissatisfied with their current treatment, mainly because of the lack of efficacy, which highlights a continued medical need for more effective and safer therapeutic agents.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/1791

[martynnx-blog]

Peptide-Based Gastrointestinal Disorders Therapeutics Market Growth Strategies 2018 – Forecast 2026, Export, Import, Growth Ratio

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptide-based gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of various GIT disorders such as short bowel syndrome, chronic constipation, and irritable bowel syndrome. In the recent past, some peptide-based therapeutics such as Trulance, Linaclotide, and Teduglutide received approval for the treatment of GIT disorders.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2028

Trulance is a guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic constipation in adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of guanylate cyclase C receptors in the intestine. It is a minimally absorbed agonist of guanylate cyclase C receptors in the intestine and is used for the treatment of chronic constipation and irritable bowel syndrome. Teduglutide is a new recombinant analogue for glucagon-like peptide (GLP) -2, a natural occurring peptide, which is secreted primarily by the lower gastrointestinal tract.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics

Frequent approval and launch of novel peptide-based gastrointestinal disorders therapeutics in key regions is expected to drive the global peptide-based gastrointestinal disorders therapeutics market growth over the forecast period.

For instance, in 2017, Synergy Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

In 2012, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food and Drug Administration approval for its drug called Linzess (linaclotide). Linzess (linaclotide) is a guanylate cyclase-C agonist used for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

In 2016, Ironwood Pharmaceuticals, Inc.’s partner, Astellas Pharma Inc., received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for Linzess (linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan.

In 2012, NPS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its drug Gattex (Teduglutide (rDNA origin)). Gattex 0.05 mg/kg/d injection is a new, recombinant analog of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal lining. It is indicated for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Sucg frequent approval is expected to cather peptide-based gastrointestinal disorders therapeutics market growth in near future.

Furthermore, increasing prevalence of gastrointestinal disorders is expected to rise the demand for peptide-based drugs, which will in turn drive the global peptide-based gastrointestinal disorders therapeutics market growth. For instance, according to the data published by the International Foundation for Functional Gastrointestinal Disorder in 2016, irritable bowel syndrome (IBS) is the most common functional gastrointestinal (GI) disorder and globally, around 10-15% of the population suffers from IBS.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Regional Analysis

North America peptide-based gastrointestinal disorders therapeutics market is expected to exhibit good growth over the forecast period, owing to presence of major players and adoption of strategies such as mergers and collaborations by them for novel peptide-based therapeutics. For instance, in February 2018, Cipher Pharmaceuticals Inc. acquired exclusive Canadian rights of the U.S. Food and Drug Administration approved drug Trulance (plecanatide) from Synergy Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will develop, market, distribute, and sell Trulance (plecanatide) in the Canadian Market.

Asia Pacific peptide-based gastrointestinal disorders therapeutics market is expected to exhibit significant growth over the forecast period, owing to increasing investments made by players in the region to receive approval of novel peptide-based therapeutics. For instance, in 2014, Ironwood Pharmaceuticals, Inc. received US$ 15 million from Astellas Pharma Inc., a Japan-based pharmaceutical company, for initiating Phase III clinical trial of Linzess (linaclotide) in Japan, and receive its approval from Japanese Ministry of Health, Labor, and Welfare in 2016. Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. were under strategic partnership since 2009 for developing and commercializing linaclotide in Japan.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Key Players

Key players operating in the global peptide-based gastrointestinal disorders therapeutics market include Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Astellas Pharma Inc., Allergan plc., and Cipher Pharmaceuticals Inc.

[titheguerrero]

The Art of Emojis in Constipation-Conversation

“Constipation is hard. Talking about it is even harder,” reads a card I received from the senior director of marketing at Synergy Pharmaceuticals.

Emojis-meet-direct-to-consumer pharmaceutical promotion in a new campaign from the drug company, which is embarking on a disease education campaign to bring greater awareness to the condition of chronic idiopathic constipation (CIC). This condition impacts 14% of the global population.

The messengers for this effort are a cast of emojis who populate a continuum from constipation-to-diarrhea and every poop step in-between. Meet The Poop Troop:

Stressed-Out Stooly

Clogged Chris

Left-Out Lumpy

Plugged-Up Paulie

Miss La Poop

Mr. Smooth

Sausage Sally

Doody Dan

Splasher Asher

Ploptimistic Peter

Squirt

Waterworks Wally

Diarrhea Dave, and

Runny Ron.

Synergy Pharmaceuticals recently published results of a survey conducted among patients and healthcare providers on the frustrations in dealing with the condition. Key findings were that:

Most patients and providers feel a lack of symptom relief and treatment satisfaction with current available products treating CIC

The key side effect of current treatments, diarrhea, is unacceptable to both patients and providers: 82% of healthcare providers and 70% of patients do not agree that diarrhea is an acceptable treatment outcome, the poll found.

This campaign has been strategically honed with a heavy dose of market research on the psychographic level, and patient/user experience. Dr. Anish Sheth, Chief of Gastroenterology at the University Medical Center of Princeton, wrote the forward in The Poop Troop booklet introducing the emojis’ clinical personae. Dr. Sheth is the co-author of the book, What’s Your Poo Telling You. This booklet is packed with humor and self-effacing puns, featuring a seal calling the concept a “Poolitzer Prize Winner,” and quoting a “Dr. John,” opining, “Sure to inspire bowels across America.”

Given the target market, the campaign has a twitter hashtag: #ConfrontConstipation. The emojis can be downloaded from the Apple App Store or Google Play store.

Health Populi’s Hot Points: I tested this concept on an N of 2 this weekend: my young Boomer husband and my Millennial daughter, who happens to be a service design student at SCAD, the Savannah College of Art and Design. Their respective reactions to this campaign were informative to me.

For the younger market research subject, who is deep into UX design, this campaign was a big hit. She found it thoughtful, informative, and entertaining. She told me that many peer-friends indeed talk about poop with each other. Some even text from the toilet while in the process of toileting.

The impact and entertainment value of the whole poop emoji-concept eluded the older market research subject. Ironically, I had just received “Emoji Love,” a planner-journaling kit from the Simple Stories company that uses emojis as a theme, including the poop emoji (the product line is part of a larger theme called, appropriately, “Carpe Diem”). It’s pictured here; see the poop emoji on the top line of the graphic. When I showed this journaling kit to my husband, just a day before I shared The Poop Troop campaign, he just shook his head and wondered why and how I could/would use this in my planner diary and journal.

That’s market research for you, and no doubt Synergy Pharmaceuticals wasn’t aiming at the head and heart of a middle-aged guy who doesn’t have to deal with CIC on a daily basis.

In the health/care ecosystem context, this medicine segment is part of what I forecast as a growing basket of self-care treatments and technologies, based on consumers’ desire to live well and fully engaging in self-health. While some observers and analysts may scoff at the concept, if you are a person dealing with CIC and similar gut and bowel conditions, tactics and tools that help us live life on our own terms — such as dealing with runny uncontrollable stools — are front-of-mind and major daily hassles.

As a DTC campaign, there are two other aspects of this strategy I like: the use of the word “confront” in the hashtag, which supports full-on health engagement and self-awareness and empowerment; and, the use of humor for a situation that the sufferer more often than not doesn’t find all that funny.

Note: Synergy Pharmaceuticals is not a client of THINK-Health. This post was written to explore the ongoing evolution of DTC promotion in healthcare, and the use of popular culture in healthcare marketing.

The post The Art of Emojis in Constipation-Conversation appeared first on HealthPopuli.com.

Article source:Health Populi

[maxihealth]

The Art of Emojis in Constipation-Conversation

“Constipation is hard. Talking about it is even harder,” reads a card I received from the senior director of marketing at Synergy Pharmaceuticals.

Emojis-meet-direct-to-consumer pharmaceutical promotion in a new campaign from the drug company, which is embarking on a disease education campaign to bring greater awareness to the condition of chronic idiopathic constipation (CIC). This condition impacts 14% of the global population.

The messengers for this effort are a cast of emojis who populate a continuum from constipation-to-diarrhea and every poop step in-between. Meet The Poop Troop:

Stressed-Out Stooly

Clogged Chris

Left-Out Lumpy

Plugged-Up Paulie

Miss La Poop

Mr. Smooth

Sausage Sally

Doody Dan

Splasher Asher

Ploptimistic Peter

Squirt

Waterworks Wally

Diarrhea Dave, and

Runny Ron.

Synergy Pharmaceuticals recently published results of a survey conducted among patients and healthcare providers on the frustrations in dealing with the condition. Key findings were that:

Most patients and providers feel a lack of symptom relief and treatment satisfaction with current available products treating CIC

The key side effect of current treatments, diarrhea, is unacceptable to both patients and providers: 82% of healthcare providers and 70% of patients do not agree that diarrhea is an acceptable treatment outcome, the poll found.

This campaign has been strategically honed with a heavy dose of market research on the psychographic level, and patient/user experience. Dr. Anish Sheth, Chief of Gastroenterology at the University Medical Center of Princeton, wrote the forward in The Poop Troop booklet introducing the emojis’ clinical personae. Dr. Sheth is the co-author of the book, What’s Your Poo Telling You. This booklet is packed with humor and self-effacing puns, featuring a seal calling the concept a “Poolitzer Prize Winner,” and quoting a “Dr. John,” opining, “Sure to inspire bowels across America.”

Given the target market, the campaign has a twitter hashtag: #ConfrontConstipation. The emojis can be downloaded from the Apple App Store or Google Play store.

Health Populi’s Hot Points: I tested this concept on an N of 2 this weekend: my young Boomer husband and my Millennial daughter, who happens to be a service design student at SCAD, the Savannah College of Art and Design. Their respective reactions to this campaign were informative to me.

For the younger market research subject, who is deep into UX design, this campaign was a big hit. She found it thoughtful, informative, and entertaining. She told me that many peer-friends indeed talk about poop with each other. Some even text from the toilet while in the process of toileting.

The impact and entertainment value of the whole poop emoji-concept eluded the older market research subject. Ironically, I had just received “Emoji Love,” a planner-journaling kit from the Simple Stories company that uses emojis as a theme, including the poop emoji (the product line is part of a larger theme called, appropriately, “Carpe Diem”). It’s pictured here; see the poop emoji on the top line of the graphic. When I showed this journaling kit to my husband, just a day before I shared The Poop Troop campaign, he just shook his head and wondered why and how I could/would use this in my planner diary and journal.

That’s market research for you, and no doubt Synergy Pharmaceuticals wasn’t aiming at the head and heart of a middle-aged guy who doesn’t have to deal with CIC on a daily basis.

In the health/care ecosystem context, this medicine segment is part of what I forecast as a growing basket of self-care treatments and technologies, based on consumers’ desire to live well and fully engaging in self-health. While some observers and analysts may scoff at the concept, if you are a person dealing with CIC and similar gut and bowel conditions, tactics and tools that help us live life on our own terms — such as dealing with runny uncontrollable stools — are front-of-mind and major daily hassles.

As a DTC campaign, there are two other aspects of this strategy I like: the use of the word “confront” in the hashtag, which supports full-on health engagement and self-awareness and empowerment; and, the use of humor for a situation that the sufferer more often than not doesn’t find all that funny.

Note: Synergy Pharmaceuticals is not a client of THINK-Health. This post was written to explore the ongoing evolution of DTC promotion in healthcare, and the use of popular culture in healthcare marketing.

The post The Art of Emojis in Constipation-Conversation appeared first on HealthPopuli.com.

The Art of Emojis in Constipation-Conversation posted first on http://ift.tt/2sF7oEr